Stocktoria
Karyopharm Therapeutics Inc. KPTI
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2013-11-06
Karyopharm Therapeutics Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $146.1M | $145.2M | $146.0M | $157.1M | $209.8M |
| R&D expense | $125.6M | $143.2M | $138.8M | $148.7M | $160.8M |
| SG&A expense | $105.2M | $115.4M | $131.9M | $145.4M | $143.8M |
| Operating income | -$90.7M | -$119.4M | -$129.5M | -$142.2M | -$98.3M |
| Interest expense | — | — | $23.8M | $25.0M | $26.0M |
| Income tax | $43,000 | $57,000 | $323,000 | $369,000 | $268,000 |
| Net income | -$196.0M | -$76.4M | -$143.1M | -$165.3M | -$124.1M |
| EPS (diluted) | $-17.93 | $-14.00 | $-18.79 | $-2.02 | $-1.65 |
| Operating cash flow | -$75.4M | -$127.5M | -$92.7M | -$149.6M | -$107.1M |
| Free cash flow | -$75.4M | -$127.6M | -$92.7M | -$149.7M | -$107.3M |
| Cash & equivalents | $60.5M | $62.5M | $52.2M | $135.2M | $190.5M |
| Inventory | $4.0M | $4.7M | $3.0M | $4.2M | $4.1M |
| Total assets | $108.4M | $164.4M | $240.4M | $358.2M | $305.3M |
| Total liabilities | $401.3M | $350.4M | $376.6M | $374.8M | $385.0M |
| Shareholders' equity | -$292.9M | -$186.0M | -$136.2M | -$16.7M | -$79.7M |
Source: SEC EDGAR filings · CIK 0001503802 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.